BRIVARACETAM | A214921 | MSN LABORATORIES PRIVATE LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
UCB, Inc. et al v. Annora Pharma Private Limited et al 3 patentsANDA 214831, 214875, 214848, 214918, 214880, 214922, 214924, 214921, 214501brivaracetam | D. Del. | 2020-07-24 | Terminated 2023-09-12 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.2603
per ea
Lowest NADAC/Unit
$0.1712
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 72205027060BRIVARACETAM 75 MG TABLET | $0.2603 | EA | Generic | — | 2026-06-17 |
| 72205027106BRIVARACETAM 100 MG TABLET | $0.2491 | EA | Generic | — | 2026-06-17 |
| 72205027160BRIVARACETAM 100 MG TABLET | $0.2491 | EA | Generic | — | 2026-06-17 |
| 72205026906BRIVARACETAM 50 MG TABLET | $0.1712 | EA | Generic | — | 2026-06-17 |
| 72205026960BRIVARACETAM 50 MG TABLET | $0.1712 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.